3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Fallopian Tube Neoplasms
1
Congenital Abnormalities
1
Central Nervous System Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Ifosfamide
15
Methotrexate
12
Doxorubicin
12
Filgrastim
10
Cisplatin
10
Cyclophosphamide
9
Etoposide
8
Gemcitabine
7
cabozantinib
6
apatinib
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
X-Rays
5
Specimen Handling
5
Sirolimus
5
Phantoms, Imaging
5
Nivolumab
5
Neoadjuvant Therapy
5
camrelizumab
4
Vincristine
4
Topotecan
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Drug Therapy
4
Docetaxel
4
Biopsy
4
regorafenib
3
palbociclib
3
olaparib
3
mifamurtide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Osteosarcoma
×
IL32 protein, human
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts